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Abstract
Objectives Our aime was to study the short- and long-term
effects of ketogenic diet on the disease course and disease-
related outcomes in patients with pyruvate dehydrogenase
complex deficiency, the metabolic factors implicated in treat-
ment outcomes, and potential safety and compliance issues.
Methods Pediatric patients diagnosed with pyruvate dehydro-
genase complex deficiency in Sweden and treated with keto-
genic diet were evaluated. Study assessments at specific time
points included developmental and neurocognitive testing, pa-
tient log books, and investigator and parental questionnaires.
A systematic literature review was also performed.
Results Nineteen patients were assessed, the majority having
prenatal disease onset. Patients were treated with ketogenic
diet for a median of 2.9 years. All patients alive at the time
of data registration at a median age of 6 years. The treatment
had a positive effect mainly in the areas of epilepsy, ataxia,
sleep disturbance, speech/language development, social func-
tioning, and frequency of hospitalizations. It was also safe—
except in one patient who discontinued because of acute pan-
creatitis. The median plasma concentration of ketone bodies
(3-hydroxybutyric acid) was 3.3 mmol/l. Poor dietary compli-
ance was associated with relapsing ataxia and stagnation of
motor and neurocognitive development. Results of
neurocognitive testing are reported for 12 of 19 patients.
Conclusion Ketogenic diet was an effective and safe treat-
ment for the majority of patients. Treatment effect was mainly
determined by disease phenotype and attainment and mainte-
nance of ketosis.
Introduction
The ketogenic diet (KD) was first introduced as an antiepilep-
tic treatment, in 1921 (Wilder 1921), but it was not until 1976
that KD was shown to be beneficial in pyruvate dehydroge-
nase complex (PDC) deficiency (Falk et al. 1976). The bio-
chemical rationale behind the metabolic effect of KD lies in
the fact that this is a high-fat, low-carbohydrate diet that
mimics the metabolic state of long-term fasting. In PDC defi-
ciency, the glycolytic end product, pyruvate, is not optimally
metabolized through the tricarboxylic acid cycle, leading to
increased production of lactate and impaired production of
adenosine triphosphatase (ATP) via the mitochondrial respira-
tory chain (Reed 1974; Robinson et al. 1987). During carbo-
hydrate deprivation, cellular energy is no longer derived from
glycolysis but from degradation of fatty acids. The ketone
bodies (3-beta-hydroxybutyrate, acetoacetate, and acetone)
generated by fatty acid oxidation serve as an alternative ener-
gy substrate to glucose for the brain (Pierre and Pellerin 2005;
Scholl-Bürgi et al. 2015).
In this study, we present the results of a Swedish
cohort of 19 pediatric patients with PDC deficiency treat-
ed with KD. The aim was to depict the short- and long-
term effects of KD on disease course and disease-related
outcomes and elucidate metabolic factors associated with
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these outcomes. Potential safety and compliance issues
related to this dietary treatment were also evaluated.
Methods
Setting
This was a longitudinal cohort study of pediatric patients di-
agnosed with PDC deficiency in Sweden and treated with KD
between January 2009 and March 2016. All patients diag-
nosed and followed according to a specific protocol
(supplementary Table e1) at the two referral centers for
inherited metabolic diseases in Sweden—the Sahlgrenska
University Hospital in Gothenburg and the Karolinska
University Hospital in Stockholm—were included.
Inclusion criteria
Inclusion criteria were:
(1) Disease onset before 18 years of age
(2) Clinical and laboratory phenotype compatible with
PDC deficiency
(3) Presence of pathogenic mutation(s) associated with
PDC deficiency
(4) Treatment with KD for a minimum of 3 months
(5) Data availability onmedical records to achieve >90% of
data point coverage on the Case Report Form (CRF).
Data analysis
Patients were prospectively evaluated at baseline then 3, 6,
and 12 months, and then every sixth month according to the
ketogenic diet protocol (Table e1). Each patient was clinically
assessed by the same physician across evaluations.
Neurocognitive development was assessed at baseline,
6 months, 12 months, and every second year with the help
of the Griffiths Mental Development Scales and the Wechsler
Scales for Children (WPPSI-III and WISC-IV), where appro-
priate, depending on patient’s chronological age and cognitive
development at baseline. The main neurocognitive outcomes
were speech and language development, performance, social
functioning, and composite score of the neurocognitive sub-
tests, indicating patient intelligence. The latter is presented as
a full-scale intelligence quotient (IQ) or general developmen-
tal quotient (GQ).
Gross- and fine-motor development was assessed by the
pediatric neurologist and physiotherapist who followed the
patient. Dietary compliance was assessed from: (a) ketosis
level based on the levels of 3-hydroxybutyric acid (ketone
bodies) measured at home with a hand-held meter and at the
laboratory at follow-up visits; (b) nutrient intake, estimated
with the help of 4-day food records collected at each follow-
up visit. Safety outcomes were assessed with the help of reg-
ular monitoring of side effects and biochemical investigations
performed in fasting state (Table e1).
The overall treatment outcome was assessed at the last
follow-up visit and compared with baseline using the
Clinical Global Impression of Improvement (CGI-I) scale,
ranging from 1 (very much improved) to 7 (very muchworse).
At the last follow-up visit, parents were asked to complete a
questionnaire sharing their perspectives of global improve-
ment from baseline to last follow-up visit. Parents were also
asked to evaluate their child’s improvement during treatment
from 1 (very much improved) to 7 (very much worse) in the
following areas: motor skills, cognitive skills, social/
behavioral skills, and epileptic seizures. Neuroradiologic ex-
amination before and after KD initiation was not part of the
protocol.
All data were retrospectively collected from patient records
with the help of a CRF. Since PDC deficiency is a rare
neurometabolic disorder, the statistical methods applied were
mainly descriptive. The two-tailed Wilcoxon signed-rank test
was used to compare lactate values before versus after KD
start. The two-tailed paired t test was used to compare morn-
ing versus evening lactate levels. A p value <0.05 was con-
sidered significant.
Systematic literature review
Study methodology is presented in Table e2.
Ethical considerations
The study was approved by the Regional Research Ethics
Committee at the University of Gothenburg, Sweden.
Results
Perinatal history
A total of 19 patients (3 boys, 16 girls) were assessed, the
majority (15/19) having prenatal disease onset based on clin-
ical and/or neuroimaging grounds. Complications of pregnan-
cy occurred in four cases: pre-eclampsia (2), oligohydramnios
(1), and gestational diabetes mellitus (1). All patients were
born at term; intrauterine growth restriction was present in
two. Disease manifestations were present at birth or occurred
soon afterward in ten patients. These diseases were mainly
microcephaly (7), congenital lactic acidosis (7), muscular hy-
potonia and feeding difficulties (4), hypothermia (2), and hy-
poglycemia (1).
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Ketogenic diet
Median age at KD initiation was 2.5 years (week 1 of life to15
years, 3 months). Seven patients received classic KD and 12
modified KD (MKD), i.e. KD, with lower ketogenic ratio; the
vast majority received ketogenic booster (Table 1). Follow-up
was a median of 2.9 years (6 months to 6 years,11 months); all
were alive at the time of data registration, at a median age of
6 years (2 years to 16 years 5 months). All but two patients
were started on lower ratios up to 2.5:1 (fat:carbohydrate plus
protein) and were changed to higher ratios ≥6 months.
Clinical efficacy
Ten patients developed epilepsy before beginning the diet; sev-
en had generalized epilepsy (2 with West syndrome), and the
remaining three had focal epilepsy with seizures occurring on a
daily basis. Nine patients had abnormal electroencephalogram
(EEG) prior to starting the KD, as follows: abnormal back-
ground (8), epileptiform activity (5), and hypsarrhythmia (1);
two patients, one with poststroke seizures and another with
focal epilepsy, became seizure free on single antiepileptic med-
ication before beginning the diet. KD had a positive effect on
epilepsy in all patients; in half, seizures disappeared within 1
year. Follow-up EEGwas available in five patients and showed
improvement in four (completely normal in 1) and worsening
in one. One patient with focal epilepsy before KD became
seizure free but had to discontinue the diet due to side effects.
After KD discontinuation, the epilepsy relapsed, and follow-up
EEG showed increased epileptiform activity.
Six patients had ataxia initially, characterized by worsening
symptom severity with infections (6/6) and carbohydrate de-
ficiency (1/6); two (patients 9 and 11) had childhood-onset
ataxia with Leigh syndrome phenotype (patient 9) and episod-
ic ataxia (patient 11). The diet positively affected ataxia in all
patients by increasing remission periods and decreasing sever-
ity and duration. The effect was sustained during infections.
Eight of 19 patients suffered from sleep disturbance prior to
KD characterized by at least one of the following: difficulty
falling asleep, fragmented nocturnal sleep, early-morning
awakening, and excessive daytime somnolence. The diet
was effective on nocturnal awakenings and excessive daytime
somnolence, but the majority of patients (6/8) still required
medication to help them fall asleep.
Brain magnetic resonance imaging (MRI) was performed
in five patients at various time points before and after initiation
of KD. No correlation between MRI findings and treatment
outcomes could be established.
Neurodevelopmental outcomes
A delay in early motor milestones was observed in most pa-
tients. At baseline, the median developmental age of gross and
fine motor skills were 8 (Q1: 0 months; Q4: 2 years) and
7.5 (Q1: 0 months; Q4: 2 years) months, respectively. The
best motor development during treatment was seen in two
patients (9 and 11) with childhood-onset ataxia. Six patients
had spasticity at baseline, with no change during treatment.
Motor development from baseline to last follow-up for each
patient separately is shown as developmental versus chrono-
logical age (Figs. 1 and e2).
Minimal or no acquisition of gross motor skills was seen in
three patients (1, 15, 16) who had no motor skills at baseline
and reached a maximum developmental age of 3 months at
last follow-up; one patient (8) with gross motor development
of 20 months did not acquire new gross motor skills. All
remaining patients presented slow but positive development
of both gross and fine motor skills during dietary treatment.
Improvement in speech and language was seen in 15 of 19
patients during KD treatment. Patients who developed mostly
in speech and language were the two with childhood-onset
ataxia and dysarthria (9, 11), and one patient with infantile-
onset disease with dysarthria (18). At last follow-up, patients
11 and 18 had normal speech and language development with
very mild dysarthria. Patient 9 had slightly delayed speech
with mild dysarthria. This patient’s verbal IQ developed from
69 at baseline to 77 1 year after KD, to 73 after 2 years, and
has been stable at 65 the last 4 years. This patient had periods
with poor dietary compliance accompanied by worsening dys-
arthria and stagnation of speech development. Three patients
(13, 14, 17) developed language skills to a minimum language
developmental age of 2.5 years at last follow-up. Slow but
positive development during treatment was seen in nine pa-
tients, from no speech at baseline to producing sounds, letters,
or a couple of words up to a developmental age of 15 months.
Two patients developed no speech (1, 16); there was no
change in speech or language skills during treatment in pa-
tients 8 and 12, the latter of whom also had severe hearing
impairment.
Patients’ behavioral and social functioning was evaluated
clinically by the neurologist—and a neuropsychologist and/or
neuropsychiatrist if required—along with parental input. All
but one patient with minimal or no social skills at baseline
becamemore active during treatment, started making eye con-
tact and seeking attention, and were considered by their par-
ents as more alert and less somnolent. The remaining patients
who had developed social skills at baseline maintained or
improved those skills over time. Three patients exhibited hy-
peractivity–impulsivity with or without aggression at baseline
(4, 8, 17), which improved during treatment in patients 4
and17 only.
Twelve of 19 patients underwent neurocognitive testing at
baseline followed by regular neurocognitive monitoring dur-
ing treatment. Composite scores derived from neurocognitive
testing at baseline and during treatment are presented as full-
scale IQ or GQ in Fig. 2. Five of these patients had profound
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Fig. 1 Gross motor development at baseline and during treatment (n = 19)
Fig. 2 Full-scale intelligence quotient (IQ) or general developmental quotient (GQ) at baseline and during treatment (n = 12).
242 J Inherit Metab Dis (2017) 40:237–245
mental retardation at baseline with unchanged GQ during
treatment. Four patients (9, 11, 13, 14) showed improved or
unchanged cognitive skills over time. In patient 9, cognitive
development was followed from 3 years prior to baseline to
5 years after KD initiation. This patient had a dramatic decline
in full-scale IQ from 83 at 5 years to 56 at 8 years, which—in
addition to worsening ataxic symptoms—motivated the fam-
ily to initiate treatment with KD. One year after KD start, the
patient’s full-scale IQ had increased from 56 to 67 and
remained stable throughout the second year of treatment,
followed by a slow decline during the next 4 years of treat-
ment to a full-scale IQ of 55, which was the same as baseline
IQ. This neurocognitive decline after 2 years of treatment was
associated with poor dietary compliance. Three patients (17,
18, 19) showed decline in full-scale IQ/GQ from baseline to
last follow-up (Fig. 2).
Lactate levels, safety, and compliance
Increased blood lactate >2 mmol/l was found in 12 of 18
patients (67%) at baseline as opposed to four of 19 at last
follow-up (21%) (p = 0.01). Side effects were observed in 13
of 19 patients: obstipation (10/13; 2/13 showed no change
prior versus after beginning KD), pancreatitis (1/13),
sialorrhea (1/13), and vomiting (1/13). Biochemical investiga-
tions were normal in all but one patient (Fig. e4). Patient 10
had mildly elevated transaminases at 6 months after diet initi-
ation of no apparent cause; 15 months, the patient was admit-
ted to the hospital with acute pancreatitis, with subsequent KD
discontinuation.
According to parental log books, the majority of patients
had plasma ketone levels (3-hydroxybutyric acid) >2 mmol/l;
morning levels were significantly lower than evening, with a
median difference of 1.4 mmol/l (0.4–2.6 mmol/l; p < 0.001).
Two patients had compliance problems (8, 9); both had pe-
riods of inadequate ketosis despite dietary adjustments,
resulting in plasma ketone levels <2 mmol/l in consecutive
measurements. Patient 9 achieved good ketosis during the first
2 years but later had intermittently poor compliance, with
ketone levels <2 mmol/l and parallel worsening in clinical
and neurocognitive outcomes.
Concomitant medications
Patients received the following cofactors and electrolyte sub-
stitutions: thiamine (18/19), carnitine (17/19), potassium cit-
rate (13/19), calcium (8/19), vitamin D3 (7/19), magnesium
(3/19), phosphorus (2/19), and dichloroacetate (2/19). Patients
received 8.5–30 mg/kg per day of thiamine, and no beneficial
effect could be seen by the treating physician or parents in any
patient. Laxatives for obstipation (10/19), antiepileptics
(6/19), and melatonin to induce sleep (5/19) were also used.
Fig. 3 Parental impression of patient’s global improvement from baseline to last follow-up (n = 15)
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Parent and investigator impression of improvement
As shown in Table 1, 18 of 19 patients were considered
by the investigators as improving at least minimally from
baseline to last follow-up. Parental impression of the die-
tary effects on motor function, cognition, social/
behavioral skills, and epilepsy is demonstrated in Fig. 3.
Most parents considered their children as being much im-
proved in cognitive and behavioral/social functioning af-
ter diet initiation. At last follow-up visit, parents were
asked at what plasma ketone levels their children
achieved optimal functioning. Parents of eight patients
replied, considering optimal plasma ketone levels as being
>2 mmol/l, with a median of 3.3 (2.1–4.5) mmol/l.
Almost all patients who were considered by investigators
as being at least much improved had ketone levels of ∼3–
3.5 mmol/l, as opposed to the remaining patients, with
ketone levels <3 or >4 mmol/l.
Systematic literature review
Results from the systematic literature review are summarized
in Table e2.
Discussion
We evaluated the effect of KD treatment in 19 pediatric
patients with PDC deficiency and found it effective and
safe for the majority. Based on our results, KD efficacy
is determined by two major variables: PDC deficiency
phenotype, and attainment and maintenance of ketosis.
Patients with the most positive treatment outcomes were
those with infantile or childhood disease onset. These
patients experienced positive effects both clinically, i.e.,
in epilepsy, ataxia, and sleep disturbance, and in the de-
velopment of motor and neurocognitive functioning. KD
was less beneficial in patients with prenatal onset and
minimal functioning upon diet initiation. In these pa-
tients, structural brain abnormalities began in utero, with
permanent brain damage leading to profound mental re-
tardation and spasticity, which cannot be reversed. These
patients experienced positive treatment effects mostly in
the areas of epilepsy, sleep, and social functioning.
The effect of KD in intractable epilepsy is well established,
with half of the treated patients achieving >50% reduction in
seizure frequency by 6 months of treatment (Hallböök et al.
2015). In our study, all patients with epileptic seizures at base-
line improved during KD treatment. In half of them, seizures
disappeared within 1 year after diet initiation.
The effect of KD on neurocognitive and social func-
tioning in PDC deficiency has not previously been
assessed. In therapy-resistant epilepsy, treatment with
KD has been associated with increased alertness and im-
proved behavioral outcomes (Hallböök et al. 2007, 2012;
Nordli et al. 2001; Pulsifer et al. 2001). Overall
neurocognitive development was evaluated by the neuro-
psychologist as being at least minimally improved (11/
12) in our study. The cognitive decline seen in patients
17, 18, and 19; Fig. 2) was not indicative of cognitive
impairment during treatment, as these patients did not
lose previously acquired skills but, on the contrary, con-
tinued to develop cognitively during treatment, albeit at a
lower rate than expected for their biological age. As
PDC deficiency is a progressive neurological disease,
untreated patients would be expected to lose previously
acquired neurocognitive skills over time. We believe that
treatment with KD counteracts this progressive
neurodegeneration.
Our patients were alive at data registration, at a medi-
an age of 6 years. This is opposed to the poor survival
outcomes shown in previous studies (DeBrosse et al.
2012; Patel et al. 2012; Wexler et al. 1997). The effect
of KD on survival was investigated by DeBrosse et al.,
and no significant correlation was found (DeBrosse et al.
2012). Our patients survived considerably longer than
those in previous studies, which could be partly ex-
plained by the fact that they were mostly girls, as girls
with early-onset disease survive longer than boys
(DeBrosse et al. 2012); dietary treatment may also have
contributed. However, the extent to which KD contrib-
utes longer survival is difficult to assess in our study or
others due to lack of a control group.
Ketosis is considered to improve lactate levels in PDC
deficiency (Falk et al. 1976). This is also shown in our
study, as blood lactate significantly declined after KD
initiation. In order to be effective, KD treatment must
lead to adequate and sustained ketosis. Wexler et al. pro-
posed the level of ketosis as the most important variable
in determining outcome of patients with PDC deficiency
(Wexler et al. 1997). Two patients in our study (8, 9)
experienced periods of poor dietary compliance, which
we consider to explain why patient 8 developed no
new gross motor or language skills during treatment or
improved in behavioral functioning. Patient 9 had peri-
odically poor compliance, which was linked to episodic
reappearance of ataxia and a slight cognitive decline.
To our knowledge, this is the first longitudinal study
on long-term efficacy and safety outcomes of KD in
patients with PDC deficiency. Based on our study, we
propose that KD be introduced as early as possible upon
diagnosing PDC deficiency, as early initiation may pre-
vent further metabolic damage to the brain. The long-
term effectiveness is highly dependent upon regular mon-
itoring of plasma ketone levels and adjusting dietary
composition to establish and sustain ketosis.
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